38021751|t|Huntington's Disease: Understanding Its Novel Drugs and Treatments.
38021751|a|An inherited neurodegenerative ailment called Huntington's disease (HD) of gradual physical impairment, cognitive decline, and psychiatric symptoms. It is brought on by a mutation of the HTT gene, which causes aberrant huntingtin protein buildup in neurons. This predominantly affects the striatum and cerebral cortex, where neuronal malfunction and eventual cell death follow. The quality index of life for both patients and their families is significantly impacted when symptoms first appear in mid-adulthood. An overview of the available therapies for HD is given in this article. Although HD has no known treatment options, there are several that try to lessen symptoms and reduce the disease's development. By lowering involuntary movements, pharmaceutical treatments like tetrabenazine and deutetrabenazine focus on motor symptoms. Antidepressants and antipsychotic medicines are also used to manage the mental and cognitive symptoms of HD. The investigation of prospective gene-based medicines is a result of research into disease-modifying medications. Reduced synthesis of mutant huntingtin protein is the goal of RNA interference (RNAi) strategies, which may halt the course of illness. Additionally, continuing research into Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated protein 9 (CRISPR-Cas9) and other gene editing methods shows promise for reversing the genetic mutation that causes HD. Individuals with HD can benefit from non-pharmacological therapies such as physical therapy, speech therapy, and occupational therapy to increase their functional abilities and general well-being. Supportive treatment, psychiatric therapy, and caregiver support groups are also essential in addressing the difficult problems the illness presents. In conclusion, tremendous progress is being made in the domain of HD treatment, with an emphasis on symptom control, disease modification, and prospective gene-based therapeutics. Even though there has been significant improvement, more study is still required to provide better therapies and ultimately discover a solution for this debilitating condition.
38021751	0	20	Huntington's Disease	Disease	MESH:D006816
38021751	71	106	inherited neurodegenerative ailment	Disease	MESH:D020271
38021751	114	134	Huntington's disease	Disease	MESH:D006816
38021751	136	138	HD	Disease	MESH:D006816
38021751	151	170	physical impairment	Disease	MESH:D059445
38021751	172	189	cognitive decline	Disease	MESH:D003072
38021751	195	215	psychiatric symptoms	Disease	MESH:D001523
38021751	255	258	HTT	Gene	3064
38021751	287	297	huntingtin	Gene	3064
38021751	393	413	neuronal malfunction	Disease	MESH:D009410
38021751	623	625	HD	Disease	MESH:D006816
38021751	661	663	HD	Disease	MESH:D006816
38021751	792	813	involuntary movements	Disease	MESH:D020820
38021751	846	859	tetrabenazine	Chemical	MESH:D013747
38021751	864	880	deutetrabenazine	Chemical	MESH:C000609690
38021751	989	998	cognitive	Disease	MESH:D003072
38021751	1011	1013	HD	Disease	MESH:D006816
38021751	1157	1167	huntingtin	Gene	3064
38021751	1500	1502	HD	Disease	MESH:D006816
38021751	1521	1523	HD	Disease	MESH:D006816
38021751	1723	1734	psychiatric	Disease	MESH:D001523
38021751	1917	1919	HD	Disease	MESH:D006816
38021751	Association	MESH:D006816	3064
38021751	Association	MESH:D003072	3064
38021751	Association	MESH:D009410	3064
38021751	Negative_Correlation	MESH:D013747	MESH:D020820
38021751	Negative_Correlation	MESH:C000609690	MESH:D020820

